NEW YORK (Reuters) - Mylan Inc said on Monday its Dey Pharma unit has settled a 2006 lawsuit brought by the U.S. Department of Justice over Medicare and Medicaid reimbursements to pharmacists and other healthcare providers.
As part of the settlement, Dey has agreed to pay $280 million without admitting any wrongdoing.
Mylan bought the specialty drug division in 2007 from Merck KGaA, after the lawsuit was filed. Under the acquisition agreement, Merck is responsible for paying the full amount of the settlement as well as all costs related to reimbursement lawsuits involving Dey, Mylan said.
Merck could not immediately be reached for comment outside business hours.
Reporting by Nick Zieminski; Editing by Muralikumar Anantharaman
Our Standards: The Thomson Reuters Trust Principles.